Fiche publication
Date publication
août 2024
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe
Tous les auteurs :
Loriot Y, Balar AV, Petrylak DP, Kalebasty AR, Grivas P, Fléchon A, Jain RK, Swami U, Bupathi M, Barthélémy P, Beuzeboc P, Palmbos P, Kyriakopoulos CE, Pouessel D, Sternberg CN, Tonelli J, Sierecki M, Zavodovskaya M, Elboudwarej E, Diehl L, Jürgensmeier JM, Tagawa ST
Lien Pubmed
Résumé
Human trophoblast cell surface antigen 2 (Trop-2) is a protein highly expressed in urothelial cancer (UC). Sacituzumab govitecan (SG) is a Trop-2-directed antibody drug conjugate with a hydrolysable linker and a potent SN-38 payload. This study explored Trop-2 expression in tumors treated with SG in cohorts 1 to 3 (C1-3) from the TROPHY-U-01 study and evaluated whether efficacy was associated with Trop-2 expression.
Mots clés
Humans, Cell Adhesion Molecules, metabolism, Antigens, Neoplasm, Antibodies, Monoclonal, Humanized, therapeutic use, Female, Male, Aged, Middle Aged, Camptothecin, analogs & derivatives, Immunoconjugates, therapeutic use, Aged, 80 and over, Adult, Biomarkers, Tumor, metabolism, Urologic Neoplasms, drug therapy, Treatment Outcome, Neoplasm Staging
Référence
Clin Cancer Res. 2024 08 1;30(15):3179-3188
